COVID-19 Vaccine Development
- Biopharmaceutical Development on COVID:19
COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
PDDS 2022 Speakers
Alena Korbut
IHS/Cherokee Nation, United States
Victoria Demina
NEUWAY Pharma GmbH, Germany
Samir Haddouchi
Sotax Pharma Services, France
Miroslav Radenkovic
University of Belgrade, Serbia
Mirjana B. Colovic
University of Belgrade, Serbia
Madhav Bhatia
University of Otago, New ZealandSubmit your abstract Today
Title : Drug Delivery to the Brain using Engineered Protein Capsules (EnPCs®)
Victoria Demina, NEUWAY Pharma GmbH, Germany
Title : Mucoadhesive systems for the fast delivery of drugs
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Hydrogen Sulfide: A Stinky Gas….. and Novel Therapeutic Target for Inflammatory Disease
Madhav Bhatia, University of Otago, New Zealand
Title : Arsenate target specific cell death mechanism in normal and tumoral breast cancer cell lines
Cornelia Braicu, Iuliu Hațieganu University of Medicine and Pharmacy, Romania
Title : Vaccines against rotavirus, data based on a study for safety and efficacy
Merita Kucuku, Freelance consultant, Albania
Title : Cardiac myosin inhibitors – New pharmacological approach for obstructive hypertrophic cardiomyopathy treatment
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Self microemulsifying systems based topical lipstick of antifungal agent
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Development and Evaluation of Structured Strategic Approach for successful accomplishment of Risk-Based Monitoring model from clinical trial inception to completion at clinical trial organization.
Heema Desai, Texila American University, India
Title : Immune checkpoint inhibitors (ICIs) and immune-related adverse drug reactions: Focus on their neurotoxicity
Liberata Sportiello, University of Campania “L. Vanvitelli”, Italy
Title : Latest trends in Bio-degradation of Xenobiotics for cleaning up the environment
Neha Agarwal, University of Lucknow, India